New pill shows promise against advanced cancers in early trial

NCT ID NCT04991480

First seen Jan 28, 2026 · Last updated May 15, 2026 · Updated 16 times

Summary

This study tested an experimental drug called ART4215 in 93 people with advanced or metastatic solid tumors (cancers that have spread). The goal was to find a safe dose and see how well it works alone or combined with other cancer drugs (talazoparib or niraparib). Participants had to have stopped all other cancer treatments before joining. The study is now complete, and results will help guide future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Florida Cancer Specialists

    Orlando, Florida, 32827, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Oklahoma University

    Oklahoma City, Oklahoma, 73104, United States

  • Sarah Cannon Research Institute

    London, England, UK/W1G 6AD, United Kingdom

  • Tennessee Oncology

    Nashville, Tennessee, 37203, United States

  • University of Pennsylvania/Abramson Cancer Center

    Philadelphia, Pennsylvania, 19104, United States

  • Yale School of Medicine

    New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.